Related Experiment Video
Updated: Feb 16, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Mirabegron Toxicosis in Dogs: a Retrospective Study
Renee D Schmid1, Lynn R Hovda2
1Pet Poison Helpline, 3600 American Blvd W #725, Bloomington, MN, 55431, USA. rschmid@petpoisonhelpline.com.
Mirabegron, used for overactive bladder (OAB) in humans, showed a high toxicity risk in dogs during preclinical trials. However, field data revealed a wider safety margin, with tachycardia and erythema as common signs, and no fatalities observed.
Area of Science:
- Veterinary Toxicology
- Pharmacology
- Canine Health
Background:
- Mirabegron is a selective beta-3 adrenoreceptor agonist used for treating overactive bladder (OAB) in humans.
- While safe in humans, preclinical trials indicated severe adverse effects and a narrow safety margin in dogs.
- Understanding the clinical effects and outcomes of mirabegron toxicosis in dogs is crucial for veterinary practice.
Related Concept Videos
Toxicity Testing in Animals
Drug Toxicity: Risk factors
Drug Toxicity: Overview
Drug Toxicity: Dose-Dependent Reactions
Toxicokinetics: Overview
Anticholinesterase Agents: Poisoning and Treatment
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...

